73,172 Shares in Organogenesis Holdings Inc. (NASDAQ:ORGO) Bought by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 73,172 shares of the company's stock, valued at approximately $234,000. XTX Topco Ltd owned approximately 0.06% of Organogenesis at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Organogenesis during the fourth quarter worth approximately $38,000. Palumbo Wealth Management LLC purchased a new stake in Organogenesis in the 4th quarter worth approximately $65,000. Mariner LLC acquired a new stake in shares of Organogenesis during the 4th quarter valued at $123,000. Wells Fargo & Company MN grew its holdings in shares of Organogenesis by 29.6% during the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after acquiring an additional 9,464 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Organogenesis by 66.4% during the 4th quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock valued at $134,000 after acquiring an additional 16,660 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley boosted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Insider Activity

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 36.90% of the stock is currently owned by corporate insiders.

Organogenesis Stock Up 4.5 %

Shares of Organogenesis stock traded up $0.21 on Tuesday, hitting $4.88. 1,879,310 shares of the company traded hands, compared to its average volume of 1,131,399. The company has a 50-day moving average price of $4.49 and a 200 day moving average price of $3.80. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 12-month low of $2.21 and a 12-month high of $6.71. The company has a market cap of $618.92 million, a PE ratio of -81.33 and a beta of 1.79.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.